Responsive Playbooks and the EMBC Inflection
This article provides an AI-generated analysis of Embecta Corp. (NASDAQ: EMBC), indicating a neutral sentiment across all time horizons with no clear price positioning signal. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and notes elevated downside risk due to a lack of long-term support signals.
Embecta Corp Stock: A Focused Leader in Diabetes Care with Proven Products and Strategic Independenc
Embecta Corp (ISIN: US29082K1051) is an independent global leader in insulin delivery devices, focusing on self-injection systems for diabetes patients. Spun off from BD in 2022, the company leverages its OneTouch pen needle platform and other established brands to serve a market driven by rising global diabetes prevalence. Key growth drivers include product innovation, market penetration in emerging regions, and strategic independence, while facing competition from both large and specialized medical device companies.
SG Americas Securities LLC Acquires Shares of 435,842 Embecta Corp. $EMBC
SG Americas Securities LLC acquired 435,842 shares of Embecta Corp. (NASDAQ:EMBC) in Q4, valued at approximately $5.18 million, representing about 0.74% of the company. Institutional investors now own 93.83% of Embecta, which pays a quarterly dividend of $0.15 (6.8% yield) and trades near $8.79. Despite beating Q4 estimates and setting FY2026 guidance, analysts maintain a consensus "Hold" rating with an average target price of $18.50.
Embecta Corp Stock: A Focused Leader in Diabetes Care with Proven Products and Strategic Independence
Embecta Corp, spun off from BD in 2022, is a specialized medical device company focused on self-injection systems, particularly for diabetes patients, with its flagship OneTouch pen needle platform. The company's business model emphasizes lean manufacturing, supply chain efficiency, and growth in emerging markets, leveraging established brands and consistent cash flow from recurring consumable sales. Key considerations for investors include its ability to innovate against competition, manage supply chain vulnerabilities, and navigate regulatory changes, while benefiting from increasing global diabetes prevalence.
JPMorgan Chase & Co. Boosts Stock Position in Embecta Corp. $EMBC
JPMorgan Chase & Co. increased its stake in Embecta Corp. (NASDAQ:EMBC) by 39.5% in the third quarter, acquiring an additional 123,113 shares to own a total of 434,822 shares. Other institutional investors like Jefferies Financial Group Inc. and Exchange Traded Concepts LLC also raised their positions in the company. Embecta recently reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend of $0.15 per share.
Embecta Corp. (NASDAQ:EMBC) Sees Large Increase in Short Interest
Embecta Corp. (NASDAQ:EMBC) experienced a 19.4% increase in short interest in March, totaling 5,617,135 shares, which represents about 9.6% of its shares short. Despite this, the company beat its recent quarterly earnings estimates with $0.71 EPS and $261.2M revenue, and issued strong FY2026 guidance. Embecta also offers a quarterly dividend of $0.15, leading to a 6.8% dividend yield, with institutional investors holding approximately 93.8% of its stock.
EMBC SEC Filings - Embecta Corp 10-K, 10-Q, 8-K Forms
This page on StockTitan provides comprehensive access to Embecta Corp.'s SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event forms. It details how Embecta uses these filings to disclose financial performance, governance changes, and strategic priorities, with StockTitan offering AI-powered summaries and real-time updates for investor analysis. The article also provides recent filing examples and key company data.
Embecta Corp. Stock Plummets to New 52-Week Low of $8.47
Embecta Corp. has hit a new 52-week low of $8.47, reflecting a significant decline in its performance over the past year. The microcap company in the Pharmaceuticals & Biotechnology sector has a market capitalization of USD 522 million and faces challenges such as a negative book value and poor return on equity. Despite an attractive dividend yield, the stock's long-term growth prospects are weak, with an annual operating profit decline of 8.07% over the past five years.
Mills & Reeve advises Owen Mumford on £150m sale to embecta Corp in New Jersey
Law firm Mills & Reeve advised the shareholders of Owen Mumford Holdings Limited on its sale to Nasdaq-listed embecta Corp for up to £150 million. The acquisition, comprising an upfront cash payment of £100 million and up to £50 million in performance-based payments, enables Owen Mumford to expand its product portfolio leveraging embecta's global presence. This move is expected to bolster embecta's revenue growth and accelerate its transformation into a broad-based medical supplies company serving chronic care patients.
Embecta Corp. Stock Plummets to New 52-Week Low of $8.68
Embecta Corp. has reached a new 52-week low of $8.68, marking a significant decline of 27.41% in its stock price over the past year. The company faces challenges including a negative book value, low return on equity, and a concerning annual operating profit growth rate of -8.07% over the last five years. Despite a dividend yield of 6.68%, its performance consistently underperforms market benchmarks, raising concerns about its long-term financial health.
Vanguard reorganizes reporting; EMBC ownership listed as 0 (EMBC)
Vanguard has filed an amended Schedule 13G/A for Embecta Corp (EMBC), reporting zero beneficial ownership (0 shares, 0%) due to an internal realignment. This change follows SEC Release No. 34-39538, where certain Vanguard subsidiaries will now report their beneficial ownership separately, thereby removing The Vanguard Group, Inc. from being deemed a beneficial owner of those securities. This amendment is an administrative disclosure regarding reporting responsibility and does not indicate a sale or transfer of EMBC shares.
Understanding the Setup: (EMBC) and Scalable Risk
This article analyzes Embecta Corp. (NASDAQ: EMBC) using AI models, identifying a neutral near-term sentiment and elevated downside risk due to a lack of long-term support signals. It provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal data for support and resistance.
Embecta to acquire Owen Mumford to expand drug-delivery portfolio
Embecta Corp. announced its intention to acquire Owen Mumford Ltd. for £172.5 million to expand its drug-delivery product portfolio, particularly for diabetes and obesity. This acquisition is expected to enhance Embecta's organic growth, provide entry into new therapy areas, and be accretive to its non-GAAP earnings per share by the end of fiscal year 2026. The deal, subject to regulatory approvals, is anticipated to close in the second half of calendar year 2024.
Embecta to Acquire Owen Mumford to Expand Drug-Delivery Portfolio
Embecta Corp. announced its acquisition of Owen Mumford Holdings Limited for up to $199.4 million to expand its drug delivery platforms beyond its core diabetes franchise. The strategic move aims to diversify Embecta's offerings into broader chronic care areas, including obesity and autoimmune diseases, and leverage Owen Mumford's Aidaptus auto-injector technology. The deal, expected to close in the third quarter of fiscal 2026, anticipates long-term revenue growth and high-single-digit returns on invested capital, despite initial dilution to net income.
Embecta Plans Acquisition of Owen Mumford to Broaden Drug-Delivery Offerings
Embecta Corp. (EMBC) announced its acquisition of Owen Mumford Holdings Limited for up to $199.4 million, aiming to expand its drug delivery offerings beyond diabetes into advanced platforms. The deal, expected to close in Q3 fiscal 2026, will leverage Owen Mumford's innovative technologies like the Aidaptus auto-injector and Embecta's global reach to drive long-term revenue growth and diversify its medical supplies business. While EMBC shares saw an initial decline, the acquisition is projected to contribute to revenue growth by fiscal 2027 and generate high single-digit returns on invested capital within four years.
Embecta Plans Acquisition of Owen Mumford to Broaden Drug-Delivery Offerings
Embecta Corp. (EMBC) has announced its definitive agreement to acquire Owen Mumford Holdings Limited for up to $199.4 million. This acquisition aims to expand Embecta's focus beyond diabetes into broader drug delivery and medical device technologies, leveraging Owen Mumford's innovative products like the Aidaptus auto-injector. The move is expected to accelerate Embecta's international growth, enhance its chronic care offerings, and contribute to revenue growth starting in fiscal 2027, despite an initial dip in EMBC shares.
Embecta to Acquire Owen Mumford to Expand Drug-Delivery Portfolio
Embecta (EMBC) has announced its definitive agreement to acquire Owen Mumford Holdings Limited for up to $199.4 million, including an upfront payment and performance-based earnouts. This acquisition aims to expand Embecta's drug delivery portfolio beyond its core diabetes franchise, focusing on high-value platforms and chronic care areas. The deal, expected to close in Q3 fiscal 2026, is anticipated to drive sustainable revenue growth and strengthen Embecta's position as a broad-based medical supplies company.
Embecta: £150 Million Acquisition Of Owen Mumford To Expand Drug Delivery Platform Capabilities
Embecta, a diabetes care technology company, is set to acquire Owen Mumford Holdings Limited, a UK-based medical device innovator, for up to £150 million. This acquisition aims to expand Embecta's drug delivery platform capabilities, particularly with Owen Mumford's Aidaptus auto-injector, and accelerate its transformation into a broader medical supplies company serving various therapeutic areas. The deal is expected to close in fiscal third quarter 2026 and contribute to Embecta's revenue growth starting in fiscal year 2027.
Embecta to Acquire Owen Mumford in £150M Deal, Expanding Drug Delivery and Chronic Care Portfolio
Embecta Corp. announced its acquisition of UK-based medical device innovator Owen Mumford Holdings Limited for up to £150 million. This strategic move aims to transform Embecta from a diabetes-focused company into a broader medical supplies and drug delivery platform, particularly expanding its reach into obesity, autoimmune diseases, and anaphylaxis markets. The deal, expected to close in fiscal Q3 2026, will integrate Owen Mumford's autoinjector platform, including its Aidaptus device, which is relevant for pharmacists counseling patients on self-injectable therapies.
Embecta to Acquire Owen Mumford, Expanding Drug-Delivery Portfolio
Embecta Corporation announced a definitive agreement to acquire UK-based medical device maker Owen Mumford Holdings Limited for up to £150 million. This acquisition is expected to expand Embecta’s drug-delivery portfolio beyond diabetes into broader chronic care markets, leveraging Owen Mumford’s auto-injector technologies. The deal is projected to close in Embecta's fiscal third quarter of 2026 and is anticipated to enhance revenue growth and operating income from fiscal 2027 onwards.
Embecta (NASDAQ: EMBC) to acquire Owen Mumford in up to £150m deal
Embecta (NASDAQ: EMBC) has announced its acquisition of UK-based medical device maker Owen Mumford Holdings Limited for up to £150 million. The deal, comprising an upfront cash payment of £100 million and up to £50 million in performance-based payments, aims to expand Embecta's presence in drug-delivery devices and chronic care, particularly with Owen Mumford's Aidaptus® auto-injector platform. This strategic move is expected to support revenue growth from fiscal year 2027 onwards and accelerate Embecta's transformation into a broader medical supplies company.
Embecta to acquire UK medical device maker Owen Mumford for $200M
Embecta, a global diabetes technology leader, announced its plan to acquire UK-based medical device maker Owen Mumford for $200 million. This acquisition, consisting of an upfront payment of $135 million and up to $65 million in earnouts, will broaden Embecta's portfolio beyond diabetes into drug-delivery technologies. The deal is expected to close by Q3 2026 and aims to accelerate Embecta's transformation into a broad-based medical supplies company, boosting its revenue starting in fiscal year 2027.
Embecta to buy Owen Mumford for up to £150M
Embecta Corp. (EMBC) has announced an agreement to acquire Owen Mumford, a manufacturer of medical devices for pharmaceutical and diagnostic companies, for a total consideration of up to £150 million. The acquisition, which includes £140 million upfront and a potential £10 million earn-out, is expected to enhance Embecta's product portfolio and market position.
The recent acquisition projects undertaken by Embecta Corp are expected to inject new momentum into the company's revenue growth in fiscal year 2027 and gradually improve profitability in subsequent fiscal years.
Embecta Corp's recent acquisitions are projected to boost the company's revenue growth starting in fiscal year 2027. These strategic investments are also anticipated to gradually enhance profitability in the years following 2027. The company expects these moves to strengthen its market position in the medical device sector.
Embecta bets up to £150M to expand from diabetes care into drug delivery
Embecta (Nasdaq: EMBC) has announced an agreement to acquire UK-based Owen Mumford for up to £150 million, consisting of £100 million upfront and up to £50 million in performance payments. This acquisition aims to expand Embecta's portfolio beyond diabetes care into drug delivery platforms, strengthening its offerings in chronic care and pharmaceutical partnerships. The deal, expected to close in Embecta’s fiscal Q3 2026, is anticipated to contribute to revenue growth and become accretive to adjusted net income after fiscal year 2027.
embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
Embecta Corp. (Nasdaq: EMBC) has announced a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device and drug-delivery technologies innovator, for up to £150 million. This acquisition is expected to significantly enhance embecta's revenue growth, expand its presence in the drug-delivery market, and accelerate its transformation into a broad-based medical supplies company, particularly by leveraging Owen Mumford's Aidaptus® auto-injector platform. The transaction, unanimously approved by embecta's Board of Directors, is slated to close in fiscal third quarter of 2026, pending regulatory approvals.
embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
Embecta Corp. announced a definitive agreement to acquire Owen Mumford Holdings Limited for up to £150 million. This acquisition aims to enhance embecta's presence in the drug-delivery device market, particularly with Owen Mumford's Aidaptus® auto-injector platform, and to transform embecta into a broader medical supplies company serving chronic care patients. The transaction, unanimously approved by embecta's Board, is expected to close in fiscal Q3 2026 and contribute to revenue growth and profitability in subsequent fiscal years.
embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
embecta has announced a definitive agreement to acquire Owen Mumford Holdings Limited for up to £150 million. This acquisition will expand embecta's presence in drug-delivery devices, accelerating its transformation into a broad-based medical supplies company and positioning it to participate in the growing market for drug-delivery devices supporting various therapies. The transaction is expected to close in embecta’s fiscal third quarter of 2026, subject to regulatory approvals.
Embecta (NASDAQ:EMBC) Reaches New 1-Year Low - Should You Sell?
Embecta (NASDAQ:EMBC) shares recently hit a new 52-week low of $8.72, trading at $8.7990 with a market cap of $519M. Despite analysts having a "Hold" consensus and a target price of $18.50, the stock is below its 50-day and 200-day moving averages. The company delivered a strong quarterly earnings beat and offers a 6.8% dividend yield, yet institutional ownership is high at almost 93.8%.
Embecta Corp. (NASDAQ:EMBC) Sees Large Increase in Short Interest
Embecta Corp. (NASDAQ:EMBC) experienced a substantial 16.6% increase in short interest in February, reaching 4,703,024 shares, which accounts for 8.0% of its float. Despite trading near its 52-week low and a consensus "Hold" rating, the company beat its quarterly earnings and revenue estimates and declared a quarterly dividend of $0.15. Institutional ownership in Embecta is high at 93.83%, with several major firms increasing their stakes.
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Simply Wall St estimates Embecta Corp.'s (NASDAQ:EMBC) fair value to be US$27.21, suggesting the stock, currently trading at US$13.69, is 50% undervalued. The valuation is derived using a 2-stage Discounted Cash Flow (DCF) model based on forecast future cash flows for ten years and a terminal value. This intrinsic value is also significantly higher than the analyst price target of US$16.67.
Embecta Corp. Stock Plummets to New 52-Week Low of $8.81
Embecta Corp. has reached a new 52-week low of $8.81, experiencing a 24.47% stock price decline over the past year. The company, a microcap player in Pharmaceuticals & Biotechnology with a market capitalization of $635 million, faces challenges including negative book value, low return on equity, and a five-year average annual operating profit decline of -8.07%. This significant underperformance against market benchmarks raises concerns about its long-term growth potential.
BTIG Lowers PT on Embecta Corp. (EMBC) to $25, Keeps a Buy Rating
BTIG has lowered its price target for Embecta Corp. (EMBC) to $25, while maintaining a Buy rating on the stock. This adjustment comes despite the retained positive outlook for the company's performance.
Embecta Corp. Stock Plummets to New 52-Week Low of $9.06
Embecta Corp. stock has fallen to a new 52-week low of $9.06, reflecting a 25.78% decrease over the past year, contrasting significantly with the S&P 500's gain. The company, a microcap in the Pharmaceuticals & Biotechnology sector, faces challenges such as negative return on equity, a high debt-to-equity ratio, and declining operating profit trends. Its market capitalization is $635 million, with a P/E ratio of 6.00 and a dividend yield of 5.49%.
The Technical Signals Behind (EMBC) That Institutions Follow
This article from Stock Traders Daily analyzes Embecta Corp. (EMBC) through technical signals, indicating weak near and mid-term sentiment, a neutral long-term outlook, and elevated downside risk. It presents institutional trading strategies including long, momentum breakout, and short positions, along with multi-timeframe signal analysis to guide investors. The report emphasizes AI-generated signals for positioning and risk management.
Embecta (NASDAQ:EMBC) Hits New 1-Year Low - Here's What Happened
Embecta (NASDAQ: EMBC) recently hit a new 52-week low of $8.78, closing at $9.00 on heavy volume. Despite slightly beating quarterly earnings and revenue expectations and offering in-line FY2026 guidance, the stock declined. The company also declared a quarterly dividend of $0.15, leading to a 6.7% yield, and analysts currently have a consensus "Hold" rating with an average target price of $18.50.
Jefferies Financial Group Inc. Boosts Stock Position in Embecta Corp. $EMBC
Jefferies Financial Group Inc. significantly increased its stake in Embecta Corp. (NASDAQ:EMBC) by 40.4% in the third quarter, now owning 1,884,875 shares valued at $26.6 million, representing 3.22% of the company. Other institutional investors also adjusted their positions, with hedge funds and institutions collectively holding 93.83% of Embecta's stock. Embecta recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.15 per share, resulting in an annualized yield of 6.6%.
EMBC SEC Filings - Embecta Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Embecta (EMBC) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details recent filings like the 2026 Annual Meeting proposals, the 2025 Annual Report highlighting key products and risks, and leadership changes. Stock Titan also offers AI-powered summaries of these documents to help investors understand their implications.
Embecta (NASDAQ:EMBC) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Embecta (NASDAQ:EMBC) from a "buy" to a "strong-buy" rating, despite a consensus "Hold" among other analysts with an average target price of $18.50. The upgrade follows Embecta beating Q4 earnings estimates with $0.71 EPS and $261.2M revenue, and issuing FY2026 guidance of $2.80–$3.00 EPS. Currently, Embecta shares are trading near a one-year low, suggesting a depressed valuation with a low trailing PE of approximately 3.8.
InvestingPro’s Fair Value spotted Embecta overvaluation before 47% drop By Investing.com
InvestingPro's Fair Value models successfully identified Embecta Corp. (NASDAQ:EMBC) as significantly overvalued in December 2024, predicting a potential 40% downside. The healthcare stock subsequently dropped 47% by March 2026, validating the analysis. This case study highlights the accuracy of InvestingPro's methodology in helping investors detect overvalued positions and make informed trading decisions.
William Blair Investment Management LLC Sells 312,857 Shares of Embecta Corp. $EMBC
William Blair Investment Management LLC reduced its stake in Embecta Corp. ($EMBC) by 15.7%, selling 312,857 shares, but still holds 2.87% of the company worth $23.7 million. Embecta recently reported strong quarterly earnings, beating expectations, and announced a quarterly dividend of $0.15 per share, yielding 6.0%. Analysts currently have a "Hold" consensus rating on the stock with an average price target of $18.50.
EMBC - Embecta Corp Latest Stock News & Market Updates
This page provides the latest news and analysis for Embecta Corp. (EMBC), a global diabetes care and medical supplies company focusing on strategic evolution and financial performance. It highlights news categories such as financial results, strategic initiatives, partnerships, corporate governance, and capital allocation. The article also includes a series of past news summaries for the company, detailing earnings reports, dividend announcements, and conference participations.
Precision Trading with Embecta Corp. (EMBC) Risk Zones
This article provides a "Precision Trading" analysis for Embecta Corp. (EMBC), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It outlines several AI-generated trading strategies including position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis also details support and resistance signals across near-term, mid-term, and long-term horizons, suggesting an exceptional risk-reward setup.
InvestingPro’s Fair Value spotted Embecta overvaluation before 47% drop By Investing.com
InvestingPro's Fair Value models had identified Embecta Corp. (NASDAQ:EMBC) as significantly overvalued at $19.51 per share in December 2024, projecting a potential downside of over 40%. The healthcare stock subsequently declined 47% to $10.26 by March 2026, validating the bearish call. This case study highlights the accuracy of Fair Value analysis in identifying overvalued stocks and helping investors make informed decisions.
Embecta Corp. (EMBC) Stock Analysis: Attractive Dividend Yield and Significant Upside Potential Beckon Investors
Embecta Corp. (EMBC), a healthcare company specializing in diabetes care solutions, presents an attractive investment opportunity due to its 5.72% dividend yield and a projected 59.03% upside potential based on analyst price targets. Despite a slight revenue contraction, the company's strong free cash flow and undervalued forward P/E ratio of 3.64 suggest robust financial health and future growth prospects. While its small-cap nature implies higher risk, its position in the growing diabetes care market makes it compelling for investors seeking both income and capital appreciation.
EMBC Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Embecta Corp (EMBC), including its income statement, balance sheet, cash flow, and key financial ratios for both annual and quarterly periods. It highlights the company's profitability, growth, liquidity, cash flow, and financial health scores like Altman Z-Score and Piotroski F-Score. The report indicates that while Embecta Corp has strong profitability and cash generation, it faces an elevated financial distress risk according to its Altman Z-Score and has negative shareholder equity.
Public Sector Pension Investment Board Increases Stock Position in Embecta Corp. $EMBC
The Public Sector Pension Investment Board significantly increased its stake in Embecta Corp. by 57.7% in Q3, owning 314,129 shares valued at approximately $4.43 million. This comes amid heavy institutional accumulation, with 93.83% of Embecta stock held by institutions. Embecta recently surpassed Q3 earnings and revenue expectations, provided positive FY2026 guidance, and declared a quarterly dividend of $0.15 for a 5.7% yield, while analysts maintain a consensus "Hold" rating.
Technical Reactions to EMBC Trends in Macro Strategies
The article provides a technical analysis of Embecta Corp. (NASDAQ: EMBC), highlighting divergent sentiment across different time horizons, which suggests choppy conditions. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also details AI-generated signals and support/resistance levels across near-term, mid-term, and long-term timeframes.
Embecta shareholders back board, pay, and equity plan
At its Annual Meeting on February 11, 2026, Embecta Corporation shareholders re-elected all seven board nominees, including CEO Devdatt Kurdikar and chair Carrie L. Anderson. They also ratified Ernst & Young LLP as the independent auditor for fiscal 2026 and approved the compensation of named executive officers. Additionally, an amendment to the 2022 Employee and Director Equity-Based Compensation Plan was endorsed to strengthen the company's ability to use equity incentives.
Form 4] Embecta Corp. Insider Trading Activity
Embecta Corp. director Karen Prange reported the acquisition of 22,841 shares of common stock on February 11, 2026, as a grant or other award at a price of $0.00 per share. Following this transaction, Prange directly beneficially owned 64,581.208 shares, which includes stock dividends. This Form 4 filing indicates a neutral impact and sentiment regarding the insider trading activity.
